Biomaterial Database

T-cell chronic lymphocytic leukemia mimicking dermatomyositis. 2000

H C Nousari, and A Kimyai-Asadi, and C H Huang, and F A Tausk

Department of Dermatology, The Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.

UI	MeSH Term	Description	Entries
D008297	Male		Males
D008875	Middle Aged	An adult aged 45 - 64 years.	Middle Age
D003882	Dermatomyositis	A subacute or chronic inflammatory disease of muscle and skin, marked by proximal muscle weakness and a characteristic skin rash. The illness occurs with approximately equal frequency in children and adults. The skin lesions usually take the form of a purplish rash (or less often an exfoliative dermatitis) involving the nose, cheeks, forehead, upper trunk, and arms. The disease is associated with a complement mediated intramuscular microangiopathy, leading to loss of capillaries, muscle ischemia, muscle-fiber necrosis, and perifascicular atrophy. The childhood form of this disease tends to evolve into a systemic vasculitis. Dermatomyositis may occur in association with malignant neoplasms. (From Adams et al., Principles of Neurology, 6th ed, pp1405-6)	Polymyositis-Dermatomyositis,Dermatomyositis, Adult Type,Dermatomyositis, Childhood Type,Dermatopolymyositis,Juvenile Dermatomyositis,Juvenile Myositis,Adult Type Dermatomyositis,Childhood Type Dermatomyositis,Dermatomyositis, Juvenile,Myositis, Juvenile,Polymyositis Dermatomyositis
D003937	Diagnosis, Differential	Determination of which one of two or more diseases or conditions a patient is suffering from by systematically comparing and contrasting results of diagnostic measures.	Diagnoses, Differential,Differential Diagnoses,Differential Diagnosis
D006801	Humans	Members of the species Homo sapiens.	Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012867	Skin	The outer covering of the body that protects it from the environment. It is composed of the DERMIS and the EPIDERMIS.
D015461	Leukemia, Prolymphocytic, T-Cell	A lymphoid leukemia characterized by a profound LYMPHOCYTOSIS with or without LYMPHADENOPATHY, hepatosplenomegaly, frequently rapid progression, and short survival. It was formerly called T-cell chronic lymphocytic leukemia.	Leukemia, T-Cell, Chronic,T-Cell Prolymphocytic Leukemia,Leukemia, Lymphocytic, Chronic, T Cell,Leukemia, Lymphocytic, Chronic, T-Cell,Leukemia, T Cell, Chronic,Lymphocytic Leukemia, T Cell, Chronic,Lymphocytic Leukemia, T-Cell, Chronic,T-Cell Leukemia, Chronic,T-Lymphocytic Leukemia, Chronic,Leukemia, T-Cell Prolymphocytic,Leukemias, T-Cell Prolymphocytic,Prolymphocytic Leukemia, T-Cell,Prolymphocytic Leukemias, T-Cell,T Cell Prolymphocytic Leukemia,T-Cell Prolymphocytic Leukemias
D017254	Leukemic Infiltration	A pathologic change in leukemia in which leukemic cells permeate various organs at any stage of the disease. All types of leukemia show various degrees of infiltration, depending upon the type of leukemia. The degree of infiltration may vary from site to site. The liver and spleen are common sites of infiltration, the greatest appearing in myelocytic leukemia, but infiltration is seen also in the granulocytic and lymphocytic types. The kidney is also a common site and of the gastrointestinal system, the stomach and ileum are commonly involved. In lymphocytic leukemia the skin is often infiltrated. The central nervous system too is a common site.	Infiltration, Leukemic,Infiltrations, Leukemic,Leukemic Infiltrations
D017809	Fatal Outcome	Death resulting from the presence of a disease in an individual, as shown by a single case report or a limited number of patients. This should be differentiated from DEATH, the physiological cessation of life and from MORTALITY, an epidemiological or statistical concept.	Fatal Outcomes,Outcome, Fatal,Outcomes, Fatal